3 603

Cited 58 times in

Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine

DC Field Value Language
dc.contributor.author안상훈-
dc.date.accessioned2014-12-19T17:45:31Z-
dc.date.available2014-12-19T17:45:31Z-
dc.date.issued2012-
dc.identifier.issn0264-410X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/92001-
dc.description.abstractAdults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B(®)). This investigational vaccine, HBsAg-1018 ISS, was well tolerated with a safety profile similar to the comparator vaccine. These results suggest that HBsAg-1018 may be more effective in this hypo-responsive population-
dc.description.statementOfResponsibilityopen-
dc.languageVACCINE-
dc.publisherVACCINE-
dc.relation.isPartOfVACCINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdjuvants, Immunologic-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntibodies, Viral/blood-
dc.subject.MESHAntibodies, Viral/immunology-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug-Related Side Effects and Adverse Reactions-
dc.subject.MESHFemale-
dc.subject.MESHHepatitis B/immunology-
dc.subject.MESHHepatitis B/prevention & control*-
dc.subject.MESHHepatitis B/virology-
dc.subject.MESHHepatitis B Surface Antigens/genetics-
dc.subject.MESHHepatitis B Surface Antigens/immunology-
dc.subject.MESHHepatitis B Vaccines/adverse effects-
dc.subject.MESHHepatitis B Vaccines/genetics-
dc.subject.MESHHepatitis B Vaccines/immunology*-
dc.subject.MESHHepatitis B virus/immunology*-
dc.subject.MESHHumans-
dc.subject.MESHImmunity, Humoral-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHOligodeoxyribonucleotides/genetics-
dc.subject.MESHOligodeoxyribonucleotides/immunology-
dc.subject.MESHPlacebos-
dc.subject.MESHToll-Like Receptor 9/agonists-
dc.subject.MESHToll-Like Receptor 9/genetics-
dc.subject.MESHToll-Like Receptor 9/immunology-
dc.titleDemonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorBenjamin P. Sablan-
dc.contributor.googleauthorDong Joon Kim-
dc.contributor.googleauthorNina G. Barzaga-
dc.contributor.googleauthorWan Cheng Chow-
dc.contributor.googleauthorMong Cho-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorSeong Gyu Hwang-
dc.contributor.googleauthorJiHyun Lee-
dc.contributor.googleauthorHamid Namini-
dc.contributor.googleauthorWilliam L. Heyward-
dc.identifier.doi10.1016/j.vaccine.2012.02.001-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ02776-
dc.identifier.eissn1358-8745-
dc.identifier.pmid22342916-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0264410X1200165X-
dc.subject.keywordHepatitis B vaccine-
dc.subject.keywordSeroprotection-
dc.subject.keywordOlder adults-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.citation.volume30-
dc.citation.number16-
dc.citation.startPage2689-
dc.citation.endPage2696-
dc.identifier.bibliographicCitationVACCINE, Vol.30(16) : 2689-2696, 2012-
dc.identifier.rimsid30062-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.